Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070525 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
A Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00070525 is a Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 90 participants, above the 28-participant average among 3 other Recurrent Childhood Medulloblastoma trials with a reported enrollment target (221% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00070525, a Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Conditions Studied
Interventions
- DRUG tipifarnib
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070525
The ClinicalTrials.gov registry entry for NCT00070525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 28-participant average among 3 other Recurrent Childhood Medulloblastoma trials with a reported enrollment target (221% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Childhood Medulloblastoma appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.
NCT00070525 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00070525 about?
NCT00070525 is a clinical study titled "Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma". This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their grow...
What is the current status of trial NCT00070525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-11.
What conditions does trial NCT00070525 study?
This clinical trial studies the following conditions: Recurrent Childhood Medulloblastoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Brain Stem Glioma, Childhood Oligodendroglioma, Recurrent Childhood Cerebellar Astrocytoma.
What interventions are being tested in trial NCT00070525?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00070525?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070525 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
COMPLETED · Phase 2
-
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Childhood Medulloblastoma
All registered trials for this condition
Childhood High-grade Cerebral Astrocytoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.